Drug Topics
DECEMBER 7, 2023
A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
STAT
DECEMBER 7, 2023
The two leaders of the Senate Budget Committee on Thursday launched a bipartisan investigation into private equity ownership of hospitals in the United States, citing concerns that such arrangements are bad for both health care providers and patients. “As private equity has moved into health care, we have become increasingly concerned about the associated negative outcomes for patients,” said Chairman Sheldon Whitehouse (D-R.I.) in a statement.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
DECEMBER 7, 2023
Two posters presented at ASHP 2023 Midyear examined how accurate answers were from the artificial intelligence chatbot.
STAT
DECEMBER 7, 2023
Imagine getting surgery without ever being cut open. Researchers at Duke University and Harvard Medical School have successfully demonstrated a proof of concept in new research published Thursday in Science using a 3D printer that uses ultrasound to print biomaterials inside an organ. Growing up, Junjie Yao, a bioengineer at Duke University and one of the primary investigators of the study, had heard stories about scientists coming up with great ideas over coffee or while chatting in the break r
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmacy Times
DECEMBER 7, 2023
Improvements in PFS were also seen among patients with brain metastases.
Fierce Healthcare
DECEMBER 7, 2023
Both the executive branch and key bipartisan legislators announced plans Thursday to tackle the negative impacts of corporate interests and ownership in healthcare. | Multiple federal agencies and bipartisan Senate leaders have launched a salvo of efforts targeting anticompetitive behaviors, high prices and private equity-involvement in the healthcare industry.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Fierce Pharma
DECEMBER 7, 2023
When it comes to manufacturing cell therapies, it's often said that the "process is the product." But churning out these complex, individualized drugs has routinely tripped up even the industry's l | In recent months, Novartis has faced scrutiny from the FDA over Kymriah production shortfalls, a newly posted letter shows. The company says it's working to address the situation.
Pharmacy Times
DECEMBER 7, 2023
Individuals with HR+ breast cancer could pause endocrine therapy for up to 2 years to become pregnant, without increasing the risk of recurrence.
STAT
DECEMBER 7, 2023
Medtronic is no longer buying EOFlow, a Korean maker of wearable insulin pumps. The news comes three months after Insulet, EOFlow’s rival, filed a lawsuit accusing the company of stealing trade secrets. In a filing with the Securities and Exchange Commission late Wednesday, Medtronic announced its cancellation of the deal. The filing is vague, citing “multiple breaches under the agreements” that allow Medtronic to renege.
Pharmacy Times
DECEMBER 7, 2023
The discussion delves into the results and implications of the clinical trials, shedding light on the efficacy and safety profile of this combination therapy.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
DECEMBER 7, 2023
In 1997, Celgene obtained a key patent for what would become a blockbuster blood cancer treatment, giving it a monopoly until 2019. But like any pharmaceutical company with an eye toward the future, Celgene continued to seek other ways to wring profits from its development work. Not long after the patent was awarded, the company leveraged federally funded research and began investigating different forms of the compound, called Revlimid.
pharmaphorum
DECEMBER 7, 2023
Partnerships for prevention: Biopharma, patients, and digital technology Mike.
STAT
DECEMBER 7, 2023
Many families take for granted the ritual of taking a newborn baby home, car seat and curated swaddle blankets in tow, just a few days after delivery. But as critical care pediatricians, we care for babies and children who often don’t fit neatly into these universal experiences. When our patients go home for the first time, they are rarely newborns.
pharmaphorum
DECEMBER 7, 2023
Treatment with Eli Lilly’s JAK inhibitor Olumiant has been shown to preserve the function of insulin-producing pancreatic beta cells in patients with type 1 diabetes, potentially opening up a whole new avenue of therapy.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Drug Store News
DECEMBER 7, 2023
CVS and Rite Aid are among the retailers offering customers gift ideas galore for the holidays, while Albertsons is kicking off savings for food, toys, meals and more and Target is offering low cost holiday meals and gifts.
pharmaphorum
DECEMBER 7, 2023
AbbVie has announced its second major takeover deal in the space of a few days, offering $8.7 billion to buy central nervous system drug specialist Cerevel Therapeutics which spun out of Pfizer in 2018.
STAT
DECEMBER 7, 2023
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. March-in mania The White House today will take a long-awaited step to potentially broaden the government’s authority to undermine patents for medicines developed with taxpayer funding — including considering a drug’s price as one part of the framework, my co-aut
pharmaphorum
DECEMBER 7, 2023
In this latest instalment of the pharmaphorum podcast, web editor Nicole Raleigh speaks with David Solomon, CEO of Mithra Pharmaceuticals, about the current women’s health landscape and what Mithra is doing on an international scale to ameliorate that.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Drug Topics
DECEMBER 7, 2023
By identifying areas of improvement and offering recommendations based on a prior cycle, investigators developed a new Plan-Do-Study-Act (PDSA) cycle to meet standards of USP.
pharmaphorum
DECEMBER 7, 2023
Biofidelity’s ASPYRE: The future is bright for oncology Mike.
STAT
DECEMBER 7, 2023
Will this be a half a loaf? After months of deliberation, the Biden administration on Thursday asserted its authority to sidestep patents in order to lower costs for some pricey medicines that were discovered with taxpayer money. But the move, which must still be finalized by an inter-agency working group, is already causing uncertainty over the extent to which drugmakers may lose valuable monopolies and consumers will save money.
Drug Store News
DECEMBER 7, 2023
Retailers, including Walgreens and Kinney Drugs are reminding consumers about flu and COVID-19 immunizations and testing offerings as the U.S. heads into peak respiratory illness season.
European Pharmaceutical Review
DECEMBER 7, 2023
Results from a world-first human trial, published in the New England Journal of Medicine , has shown that a drug called baricitinib has promise as the first disease-modifying treatment of its kind for type 1 diabetes, that can be administered as a tablet. baricitinib… [demonstrated an ability to] preserve the body’s own insulin production and suppress the progression of type 1 diabetes in people who initiated treatment within 100 days of diagnosis” The researchers noted that baricit
Drug Store News
DECEMBER 7, 2023
Dollar General's same-store sales in the third quarter of 2023 included declines in each of the home, seasonal, apparel and consumable categories.
pharmaphorum
DECEMBER 7, 2023
Medtech giant Medtronic has decided not to go ahead with a planned acquisition of EOFlow, a developer of patch-based insulin pumps, saying that there have been “multiple breaches” of their takeover agreement.
Drug Store News
DECEMBER 7, 2023
Bubble Skincare's products are set to hit shelves at the new beauty-only Boots U.K. located at Battersea Power Station, as well as online.
Fierce Pharma
DECEMBER 7, 2023
In the currently mismatched CD38 antibody race, Sanofi’s Sarclisa has delivered a pivotal trial win, which might help the lagging follower level the playing field a little. | In the currently mismatched CD38 antibody race, Sanofi’s Sarclisa has delivered a pivotal trial win, which might help the lagging follower level the playing field a little with Johnson & Johnson.
Pharmaceutical Technology
DECEMBER 7, 2023
The FDA has granted fast track designation to Solid Biosciences’s gene therapy SGT-003 for the treatment of DMD.
Fierce Pharma
DECEMBER 7, 2023
Merck has called it quits on another attempt to enhance its powerful PD-1 inhibitor Keytruda in non-small cell lung cancer (NSCLC). | Merck has called it quits on another attempt to enhance its powerful PD-1 inhibitor Keytruda in non-small cell lung cancer just as its TIGIT program goes up in flames.
Pharmaceutical Technology
DECEMBER 7, 2023
Japan has granted approval for the sBLA of Bristol-Myers Squibb (BMS) for Abecma to treat relapsed or refractory multiple myeloma (RRMM).
Fierce Pharma
DECEMBER 7, 2023
It’s been more than three years since Bristol Myers Squibb’s powerhouse immuno-oncology combination treatment of Opdivo and Yervoy has scored a combined FDA approval. | It’s been more than three years since Bristol Myers Squibb’s powerhouse immuno-oncology combination treatment of Opdivo and Yervoy has scored a combined FDA approval. But the duo could be on its way to a new endorsement based on a phase 3 trial that shows it can keep certain first-line colorectal cancer patients alive longer than
pharmaphorum
DECEMBER 7, 2023
Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate more than €10 billion ($11 billion) in annual sales by the end of the decade, a sharp increase on earlier predictions.
STAT
DECEMBER 7, 2023
White House officials will take more time to review a sweeping plan from U.S. health regulators to ban menthol cigarettes , an unexpected delay that anti-tobacco groups fear could scuttle the long-awaited rule. Administration officials indicated Wednesday the process will continue into next year, targeting March to implement the rule, according to an updated regulatory agenda posted online.
Expert insights. Personalized for you.
232 
Let's personalize your content